MK-6194 clinical trials
Also written MK-6194 and PT101.
- studies test it
- 6
- open now
- 0
- in phase 3
- 0
- first study started
- 2021
How each study uses MK-6194 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
Studies by the year they started
6 studies that test it; most in 2023 (3)
| Year | Studies |
|---|---|
| 2021 | 1 |
| 2022 | 1 |
| 2023 | 3 |
| 2024 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 6 · Other 0
Studies
Open first, then newest update. How each study uses MK-6194 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 6
- Efficacy and Safety of MK-6194 in Adult Participants With Systemic Lupus Erythematosus (MK-6194-006)TerminatedPhase 2Merck Sharp & Dohme LLCNCT06161116Written as MK-6194
- A Clinical Study of MK-6194 for the Treatment of Vitiligo (MK-6194-007)TerminatedPhase 2Merck Sharp & Dohme LLCNCT06113328Written as MK-6194
- A Study of MK-6194 (PT101) in Participants With Active Ulcerative Colitis (UC) (MK-6194-002)CompletedPhase 1Merck Sharp & Dohme LLCNCT04924114Written as MK-6194
- Multiple Rising Dose Study of MK-6194 in Participants With Atopic Dermatitis (MK-6194-008)CompletedPhase 1Merck Sharp & Dohme LLCNCT05450198Written as MK-6194
- A Single Dose Study of MK-6194 in Healthy Chinese Participants (MK-6194-014)CompletedPhase 1Merck Sharp & Dohme LLCNCT06821334Written as MK-6194
- MK-6194 Site of Injection Study in Healthy Adult Participants (MK-6194-013)CompletedPhase 1Merck Sharp & Dohme LLCNCT06649877Written as MK-6194